Response of Elevated Methylmalonic Acid to Three Dose Levels of Oral Cobalamin in Older Adults

• Published in: Journal of the American Geriatrics Society (JAGS) 2002-11, Vol.50 (11), p.1789-1795
• Main Authors: Rajan, Suparna, Wallace, Jeffrey I., Brodkin, Kayla I., Beresford, Shirley A., Allen, Robert H., Stabler, Sally P.
• Format: Article
• Language: English
• Subjects: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Biological and medical sciences; cobalamin; Cobalamin deficiency; Dietary supplements; Dose-Response Relationship, Drug; Elderly people; Female; Homocysteine - blood; Humans; Levels; Male; Medical sciences; Metabolic diseases; Methylmalonic acid; Methylmalonic Acid - blood; Nutrition; Older people; Oral administration; Other nutritional diseases (malnutrition, nutritional and vitamin deficiencies...); Pilot Projects; senior's nutrition; Supplements; Time Factors; total homocysteine; Vitamin B; Vitamin B 12 - administration & dosage; Vitamin B 12 - pharmacology; Vitamin B 12 - therapeutic use; Vitamin B 12 Deficiency - drug therapy; vitamin B12 treatment; vitamin supplements
• ISSN: 0002-8614; 1532-5415
• DOI: 10.1046/j.1532-5415.2002.50506.x

OBJECTIVES: Because the effects of lower‐dose oral cobalamin (Cbl) supplements on older people with cobalamin deficiency are not known, we determined whether oral Cbl supplements at three different dose levels would normalize elevated serum methylmalonic acid (MMA) and total homocysteine (tHcy) concentrations. DESIGN: Sequential nonrandomized intervention study of three dose levels. SETTINGS: Two university‐based senior care clinics. PARTICIPANTS: Twenty‐three older adults (aged ≥65) with serum Cbl levels of 221 pmol/L (300 pg/mL) or lower and serum MMA greater than 271 nmol/L who had been enrolled in a previous screening study for Cbl deficiency (mean age 79 ± 9; 17 male, 6 female; 17 white, 6 other). INTERVENTION: Sequential daily treatment with 25 μg oral cobalamin, followed by 100 μg and 1,000 μg cobalamin each for a 6‐week period. MEASUREMENTS: Serum MMA, tHcy, and other metabolites at baseline and after each 6‐week dosing interval. RESULTS: Treatment with 25 μg and 100 μg lowered but did not normalize MMA levels in most subjects. A dose of 1,000 μg/day proved to be the most effective in lowering MMA levels to within normal limits. Serum tHcy was normalized in six of 11 subjects who had elevated tHcy pretreatment with oral Cbl alone and in one subject in combination with a multivitamin. CONCLUSIONS: Most Cbl‐deficient older people require more than 100 μg of oral Cbl to normalize serum MMA, which is a larger dose than is available in most standard multivitamins and Cbl supplements.